Capstone Investment Advisors
DAWN

Capstone Investment Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Capstone Investment Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.06M Buy
+236,000
New +$3.33M 0.01% 415
2025
Q4 		– Sell
-22,642
Closed -$160K – 1702
2025
Q3 		$160K Buy
+22,642
New +$156K ﹤0.01% 1854
2023
Q4 		– Sell
-11,088
Closed -$136K – 2157
2023
Q3 		$136K Buy
+11,088
New +$145K ﹤0.01% 1903

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Capstone Investment Advisors's DAWN Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 236,000 shares worth $5.06M. The stake represents 0.01% of the portfolio and ranks #415 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in DAWN as recently as Q3 2025.

Capstone Investment Advisors first reported a position in DAWN in Q3 2023 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Capstone Investment Advisors held 236,000 shares of Day One Biopharmaceuticals worth $5.06M as of Q1 2026.
  • Day One Biopharmaceuticals was a new Capstone Investment Advisors position in Q1 2026.
  • Day One Biopharmaceuticals made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #415 holding.
  • Capstone Investment Advisors first reported a position in Day One Biopharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.